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An anthropomorphic head phantom, constructed from a water-equivalent plastic 
shell with only a spherical target, was modified to include a nonspherical target 
(pituitary) and an adjacent organ at risk (OAR) (optic chiasm), within 2 mm, simu-
lating the anatomy encountered when treating acromegaly. The target and OAR 
spatial proximity provided a more realistic treatment planning and dose delivery 
exercise. A separate dosimetry insert contained two TLD for absolute dosimetry 
and radiochromic film, in the sagittal and coronal planes, for relative dosimetry. 
The prescription was 25 Gy to 90% of the GTV, with ≤ 10% of the OAR volume 
receiving ≥ 8 Gy for the phantom trial. The modified phantom was used to test the 
rigor of the treatment planning process and phantom reproducibility using a Gamma 
Knife, CyberKnife, and linear accelerator (linac)-based radiosurgery system. 
Delivery reproducibility was tested by repeating each irradiation three times. TLD 
results from three irradiations on a CyberKnife and Gamma Knife agreed with the 
calculated target dose to within ± 4% with a maximum coefficient of variation of 
± 2.1%. Gamma analysis in the coronal and sagittal film planes showed an average 
passing rate of 99.4% and 99.5% using ± 5%/3 mm criteria, respectively. Results 
from the linac irradiation were within ± 6.2% for TLD with a coefficient of varia-
tion of ± 0.1%. Distance to agreement was calculated to be 1.2 mm and 1.3 mm 
along the inferior and superior edges of the target in the sagittal film plane, and 
1.2 mm for both superior and inferior edges in the coronal film plane. A modified, 
anatomically realistic SRS phantom was developed that provided a realistic clinical 
planning and delivery challenge that can be used to credential institutions wanting 
to participate in NCI-funded clinical trials.
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It has been shown that pituitary adenomas, such as acromegaly, can be safely and effectively 
treated with stereotactic radiosurgery (SRS).(1,2) Frequently used radiosurgery systems for 
treating such brain lesions include Gamma Knife,(1,3-5) CyberKnife,(1,6,7) and linear accelerator 
(linac)-based treatments.(1,8,9) Because each system involves higher-than-normal doses per frac-
tion and steep dose gradients,(2,8) there is an increased importance to accurately delivering the 
treatment to the patient.(2) Otherwise, the consequences can be devastating, as recently reported 
in the press.(10-17) It has been found that the most effective means of reducing the likelihood of a 
medical event (defined as a deviation in delivered dose by greater than 10% from the prescrip-
tion dose) is to attempt to reduce human errors involved in the radiation treatment.(18)
In assessing the quality of the overall treatment procedure, patient-image acquisition, treat-
ment planning, and dose delivery should all be considered. As a result, a simple homogenous 
phantom may not be adequate.(19) By designing a humanoid-shaped phantom with critical 
structures and heterogeneities, the overall treatment procedure may be more effectively 
evaluated.(19,20) 
Currently, for quality assurance and credentialing institutions in clinical trials involving SRS, 
the Radiological Physics Center (RPC) uses an anthropomorphic head phantom with a simple, 
spherical target of diameter 1.9 cm. Treatment criteria and SRS guidelines were established 
by the RPC in conjunction with the Radiation Therapy Oncology Group (RTOG) to assess an 
institution’s ability to adequately deliver an SRS treatment.(21) Phantom results are evaluated 
based on the following four criteria: 1) ratio of measured dose to reported dose at the center 
of the target to be 1.00 ± 0.05; 2) ratio of measured treated volume to reported treated volume 
falls within the range of 0.75–1.25; 3) minimum dose to the target is ≥ 90% of the prescrip-
tion dose; and 4) treated volume to target volume ratio is between 1.00 and 2.00.(21) During 
phantom evaluation, the reported treated volume is determined from the prescription isodose 
line reported by the institution’s treatment planning system. The measured treated volume is 
an ellipsoid, with diameters determined from the location of the prescription dose located on 
the orthogonal film profiles. The target volume is that corresponding to the 1.9 cm diameter 
spherical structure in the imaging insert of the phantom. 
It has been reported that even with a single simple target, the majority of institutions irradiat-
ing this phantom fail to meet all four criteria,(21) indicating a need for this QA tool to improve 
patient treatments.(21)
With input from the RTOG and Advanced Technology Consortium (ATC), it was determined 
that there was a need for a more rigorous test in credentialing institutions participating in SRS 
clinical trials. To address that need, the phantom commissioned in this study was a redesigned 
form presented by Balter et al.(22) As detailed by Molineu et al.,(20) these anthropomorphic 
phantoms need to be lightweight and durable so that they may be inexpensively mailed to 
institutions; the outer shell should be human-like so that it mimics realistic anatomic clinical 
setups; they should contain a target volume and organs at risk; and they should be capable of 
holding dosimeters to verify the accuracy of the plan delivery.(20)
The aim of this study is to address the need for a more rigorous test in credentialing insti-
tutions that wish to participate in SRS clinical trials. To that end, a phantom was designed, 
developed, and tested for reproducibility to assess the overall usefulness of the phantom as a 
credentialing tool for SRS delivery by a Gamma Knife radiosurgery system, CyberKnife robotic 
radiosurgery system, and standard linac-based radiosurgery system.
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II. MAterIAls AND MethoDs
A.  Phantom design     
The anthropomorphic outer shell, as shown in Fig. 1, was constructed of hollow plastic and 
supplied by The Phantom Laboratory (Salem, New York). The realistic size and human-like 
features of this outer shell allow for the use of most stereotactic immobilization devices. At 
the base of the phantom, a PVC pipe and fitting are used for filling the hollow phantom with 
water. To minimize the accumulation of air bubbles within the filled shell, a small hole near 
the base allows for air to escape while filling the phantom shell. A cylindrical recess in the base 
extends into the shell until just below the phantom head’s crown. This allows for the insertion 
of cylindrical imaging and dosimetry inserts, shown to the right of the head shell in Fig. 1. 
Modifications to the original SRS phantom design, which contained only a spherical target in 
the imaging insert, included changing the target shape to be an ellipsoid (based on the pituitary) 
measuring 2.5 cm, 1.9 cm, and 1.3 cm in the AP, left/right, and SI directions, respectively, and 
adding an adjacent (2 mm superior) organ at risk (OAR) (optic chiasm). The V-shaped OAR 
measured 0.65 cm thick in the SI direction, 0.8 cm at the base of the V, and 2.5 cm at the wid-
est part of the V in the left/right direction. The extent of the OAR along the AP direction was 
3.85 cm. These organs simulated those encountered when treating acromegaly, as seen in Fig. 2. 
The target and OAR proximity provided a more realistic treatment planning and dose delivery 
exercise than the original single spherical target design. Similar to the outer shell, the imaging 
insert was constructed to be hollow and watertight to reduce weight, while still allowing for 
tissue-like conditions during the imaging process. A separate dosimetry insert placed within the 
head recess during treatment delivery contained two thermoluminescent dosimeters (TLD) for 
point dosimetry comparison, and radiochromic film in the sagittal and coronal planes for 2D 
dosimetry, similar to that described previously by Balter et al.(22) and Amador et al.(21)  
Fig. 1. The anthropomorphic outer shell to the phantom (left), the dosimetry insert containing radiochromic film and TLD 
(middle), and the modified imaging insert containing the target and OAR (right) are shown.
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B.  Phantom dosimeters
As the means for evaluating point-based dosimetry, TLD-100 powder, in small capsules, was 
placed into the dosimetry insert used during irradiation. With respect to the center of the target, 
the TLDs are 3 mm left, 3 mm posterior, and 2.5 mm superior and 3 mm right, 3 mm anterior, 
and 2.5 mm inferior, respectively. The capsules are about 15 mm in height and 5 mm in diam-
eter, and have a 1 mm wall thickness. Each capsule contained about 20 mg of TLD powder, 
enough for a single reading. 
After irradiation, TLDs were read by using an established reading procedure.(23) Briefly, 
this involves a two-stage calibration process that corrects for batch specific properties (e.g., 
dose-response linearity, energy dependence, and fading corrections) and TLD reader system 
constancy. The latter calibration is done by irradiating TLD to a known dose from a cobalt-60 
system in order to determine the system sensitivity. Periodic checks during readout sessions 
verify reader consistency. The final TLD reading has a reported uncertainty of ± 2%.(23,24)
As a means of measuring 2D dose distributions, radiochromic films (GAFCHROMIC MD-55 
film; Nuclear Associates, Carle Place, NY) were used. The high spatial resolution, low spectral 
sensitivity, tissue equivalence, and lack of angular dependence all made the film a good dosimeter 
for steep dose gradients found in SRS plans. Two sheets of film were oriented in the sagittal and 
coronal planes of the phantom and were located such that the intersection of the film closely 
corresponded to the center of the target as viewed from the transverse cross section. Each film 
sheet measures approximately 6 × 6 cm2. Six small holes in the dosimetry insert allowed for 
each film to be pricked with a needle in order to ensure proper spatial registration with respect 
to the phantom and treatment plan data. 
After irradiation, all films were stored together such that they had the same temperature, light 
exposure, and background radiation levels. Reading of film was performed using a 633 nm laser 
CCD transmission densitometer (Personal Densitometer SI; Molecular Dynamics, Sunnyvale, 
CA) with a scanning resolution of 0.1 mm. A mask to reduce light contamination was placed 
around each film during scanning. A dose response curve for the batch of film used was 
determined to correct for nonlinearities in the film’s dose response. All irradiated films were 
from the same lot of film. Each film was saved as a 12-bit tagged image film format file, and 
an average background from an unexposed piece of film was subtracted before film  analysis. 
Fig. 2. Transverse view of patient MRI (left) with optic apparatus and transverse view of phantom with proposed target 
(red) and OAR (green).
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During analysis, the film’s dose distribution was normalized to the measured TLD dose in 
the phantom.
C.  reproducibility studies
CT images obtained with the imaging insert in place were used to create a treatment plan that 
met the dose prescription and normal tissue constraints as specified by a proposed acromegaly 
clinical trial. However, the clinical trial constraints were modified for this phantom to make 
the objective achievable for the phantom anatomy. Specifically, the dose constraint to the optic 
chiasm was modified from ≤ 1% of the OAR volume receiving 8 Gy to being ≤ 10% of the 
OAR volume receiving 8 Gy. The phantom dose limits alongside the proposed clinical trial 
specifications are listed in Table 1. 
Three different treatment plans, adhering to the agreed dose specifications listed in Table 1 
were generated, one for each of three treatment delivery systems: a Gamma Knife radiosurgery 
system (Elekta AB, Stockholm, Sweden), CyberKnife robotic radiosurgery system (Accuray, 
Sunnyvale, CA), and linac delivery using a Varian Novalis machine (Varian Medical Systems, 
Palo Alto, CA). Plans for the three modalities were created using Leksell GammaPlan v8.3.1, 
MultiPlan v3.5.4 (Elekta), and BrainLAB Novalis Treatment Planning v5.32 (BrainLAB AG, 
Feldkirchen, Germany), respectively. The phantom was irradiated three consecutive times with 
minimal disturbance of phantom positioning when exchanging dosimeters between irradiations 
for each plan to test for reproducibility and dose delivery accuracy. Plans consisted of a 15-shot 
Gamma Knife plan, an 87-node 190 beam CyberKnife plan, shown in Fig. 3, and a two-conformal 
arc linac-based plan. CT slice thicknesses used in treatment planning were 1.00 mm for Gamma 
Knife and linac-based plans, and 1.25 mm for the CyberKnife plan. Gamma Knife and linac 
deliveries used a Leksell stereotactic head frame and BrainLAB frame less immobilization 
device, respectively, while CyberKnife utilized orthogonal kV images for position verification 
before and throughout delivery. The TLDs from each irradiation were read two weeks after 
irradiation. Point comparisons of treatment plan calculated doses at the location of the TLD and 
measured dose data were done using the average of the two measured to reported dose ratios. 
A 2D gamma analysis comparing the calculated dose distribution to the measured dose distri-
bution using the film dose distribution normalized to the TLD doses was performed. Gamma 
analysis was performed using an in-house program executed in MATLAB (The MathWorks, 
Natick, MA). When an institution’s TPS does not allow for the plan to be exported in DICOM/
RT format, an equally acceptable means of 2D analysis is measuring distance to agreement from 
dose profiles. For this reason, in evaluating the linac-based plan, the dose planes of interest were 
exported as ASCII files and compared to film manually in MATLAB. The reported DTA was 
the average from three measurements at 0.25, 0.50, and 0.75 of the maximum TPS-calculated 
dose along the profile. 
Table 1. Dose prescription and constraint specifications for treatment of pituitary adenoma.
	 Structure	 Trial	Specifications	 Phantom	Specifications
 Pituitary Adenoma 25 Gy to at least 90% of GTV 25 Gy to at least 90% of GTV
 Optic Apparatus (chiasm and optic nerves) < 10 Gy maximum dose (0.01 cc) < 10 Gy maximum dose (0.01 cc)
  ≤ 1% volume receiving 8 Gy ≤ 10% volume receiving 8 Gy
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D.  Dosimeter registration
In order to perform the gamma analysis and compare reported TPS calculated data with the mea-
sured doses, the positioning of the phantom film dosimeters was registered with the coordinate 
system of the TPS dose distribution. The film registration was performed using six pinpricks 
made in the radiochromic film prior to irradiation and related to the known coordinate of each 
pinprick relative to the center of the dosimetry insert. By registering the pinpricks during film 
analysis and comparing the distances between points to measured values, the phantom was suc-
cessfully registered with a high degree of reproducibility. Multiple measurements demonstrated 
registration agreement for all irradiations to be within 0.4 mm.   
e.  Verification of phantom geometry
Because the TPS-calculated data are registered to the imaging insert and the film is registered 
to the dosimetry insert, it is necessary to ensure proper spatial relationship between the two 
different inserts. The phantom was imaged using an AcQsim CT scanner (Phillips Healthcare, 
Amsterdam, The Netherlands) with a Leksell stereotactic frame (Elekta) for immobilization. 
Using the generated images at a 1 mm slice spacing from scans with both the dosimetry insert 
and imaging insert in place, the positional relationship of the center of the target in the imaging 
insert and the intersection of the films within the dosimetry insert was determined. 
 
Fig. 3. Isodose lines in the axial (left), sagittal (top right), and coronal (bottom right) planes at isocenter, taken from the 
CyberKnife treatment plan are shown as an example of a treatment plan that meets the established credentialing criteria.
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III. results & DISCUSSION
A.  Verification of phantom geometry
The agreement between the dosimeter and imaging inserts was found to be within 0.2 mm in the 
lateral direction, 0.2 mm in the anteroposterior direction, and 0.7 mm in the superior–inferior 
direction. With submillimeter agreement in each direction, it was determined that comparison 
between measurement and dose calculation could be accurately performed. The position of 
the V-shaped organ at risk relative to the target was also confirmed to be 2 mm superior to the 
superior edge of the target.
B.  treatment planning criteria
Development of the treatment planning criteria that institutions must meet in a quality assur-
ance audit needed to provide clinically realistic challenges while being reasonably achievable 
given the phantom design. To address the latter point, the dose constraints on the OAR were 
relaxed from ≤ 1% of the OAR volume receiving 8 Gy to ≤ 10% of the OAR volume receiving 
8 Gy. It was found that the close proximity of the OAR to the target (2 mm spacing) made it 
unreasonably difficult to deliver an adequate dose to the target while sparing the mock OAR of 
excess dose under the original definition. While this may not match the clinical criteria exactly, 
it was felt that, for the purpose of a quality assurance audit, a participating institution’s ability 
to meet predefined dose constraints would still be adequately tested. 
C.  Phantom dosimetry reproducibility
The phantom was irradiated three times with each radiosurgery system, to test for reproduc-
ibility. The calculated coefficient of variation, shown in Table 2, for the averaged TLDs were 
± 2.1%, ± 0.9%, and ± 0.1%, for Gamma Knife, CyberKnife, and linac-based deliveries, 
respectively. These numbers were low enough to imply acceptable reproducibility in an audit-
ing and credentialing tool.  
In terms of dose agreement, performance of Gamma Knife and CyberKnife irradiations 
showed average measured to TPS-calculated dose ratios of 0.96 and 1.02, respectively. The 
measured to TPS-calculated dose ratio was 0.94 for the linac-based delivery and was outside 
the proposed ± 5% credentialing criterion. Closer inspection of the individual TLDs showed 
that the right anterior–inferior TLD was located in a region of steep dose falloff for the linac 
plan in which even a small shift of 1 mm or 2 mm will result in unacceptable underirradiat-
ing of the TLD. The average measured to reported value of 0.91 in this specific TLD reflects 
this. While this error would result in a failure for the audited institution, the small coefficient 
of variation in the linac deliveries still supports the high degree of reproducibility in phantom 
performance that this study aimed to show.
Gamma analysis(25) of the coronal and sagittal film planes using a global criterion of 
± 5%/3 mm yielded coefficients of variation displayed in Table 3 of ± 0.1% and ± 1.0% in the 
coronal planes for Gamma Knife and CyberKnife deliveries, respectively, and ± 0.7% and 
± 0.2% in the sagittal plane for Gamma Knife and CyberKnife deliveries, respectively. As with 
the absolute dose, this low coefficient of variation indicates a high degree of reproducibility, 
which was desired for this phantom. 
Table 2. Reproducibility results for TLD measurements in three irradiations of the phantom using Gamma Knife, 
CyberKnife, and linac delivery systems.
 Averaged TLD Results 
 Radiosurgery System Meas./Reported σ	 %σ
 Gamma Knife 0.96 0.02 2.1%
 CyberKnife 1.02 0.01 0.9%
 Linac 0.94 0.001 0.1%
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In terms of absolute gamma rates, the passing rates for Gamma Knife and CyberKnife 
deliveries were high, averaging 99.7% and 99.2%, respectively.
A visual inspection of the gamma maps identified a general trend of the areas where pixels 
were nearest the failing criteria for Gamma Knife and CyberKnife deliveries, shown in Fig. 4. 
The Gamma Knife showed the peripheral space surrounding the target to be closer to exceeding 
the ± 5%/3 mm criteria, while CyberKnife appeared to be more challenged at the very edges 
of the target. While these regions showed systematic trends in being nearer to the maximum 
allowable difference, the overwhelming majority of the pixels were still within the passing 
criteria, as shown in Table 4.
Because the institution’s TPS was unable to export the plan in DICOM/RT format, distance-
to-agreement criteria were used for evaluation of the linac-based plan. The dose planes of interest 
were exported as ASCII files and compared to film manually in MATLAB, as shown in Figs. 5 
and 6. DTA for the superior and inferior edges of the coronal and sagittal films, presented in 
Table 3, were 1.2 mm, 1.3 mm, 1.2 mm, and 1.2 mm, respectively. DTAs were measured along 
these profile edges due to the superior placement of the organ at risk with respect to the target 
in the imaging insert.  
Table 3. Reproducibility results for gamma analysis in three irradiations of the phantom using Gamma Knife and 
CyberKnife delivery systems.
 Gamma Analysis (±5%/3 mm) 
 Coronal Film Sagittal Film
 Radiosurgery System Passing Pixels σ	 %σ	 Passing Pixels σ	 %σ
 Gamma Knife 99.9% 0.1 0.1% 99.4% 0.7 0.7%
 CyberKnife 98.8% 1.0 1.0% 99.5% 0.2 0.2%
Fig. 4. Gamma maps taken from coronal films of CyberKnife irradiation (left) and Gamma Knife irradiation (right) are 
shown. The overlaid purple outline represents the target location.
Table 4. Reproducibility results for distance-to-agreement measurements in three irradiations of the phantom using 
a linac-based delivery system.
 Inferior Edge Superior Edge
  DTA Std. Dev. DTA  Std. Dev.
 Film Plane (mm) (mm) (mm) (mm)
 Sagittal 1.2 1.1 1.3 1.0
 Coronal 1.2 1.1 1.2 1.0
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IV. CoNClusIoNs
Modifications made to the imaging insert of a previously developed head phantom have pro-
vided a realistic clinical planning and delivery challenge to audited institutions. The inclusion 
of a target and critical structure that mimic real human anatomy provide for a more clinically 
relevant test when assessing institutions ability to deliver consistent and accurate radiation 
doses. The improved design and modified dose specifications have provided a thorough means 
of evaluating stereotactic radiosurgery from start to finish.
Reproducibility tests on the phantom using three means of treatment delivery, Gamma Knife 
radiosurgery system, CyberKnife robotic radiosurgery system, and standard linear accelera-
tor delivery, showed the phantom performed in a consistent manner. Results indicate that the 
phantom provides a high degree of reproducibility under carefully controlled conditions. This 
demonstrates the usefulness of the phantom as a quality assurance tool in the evaluation of 
treatment accuracy for improving patient safety and the credentialing of institutions participat-
ing in clinical trials utilizing stereotactic radiosurgery.
 
Fig. 5. Dose profiles of film measurement (blue) and TPS reported (green) doses from linac-based delivery along the 
superior–inferior direction of the coronal film plane. Position coordinates correspond to those established by the TPS.
Fig. 6. Dose profiles of film measurement (blue) and TPS reported (green) doses from linac-based delivery along the 
superior–inferior direction of the sagittal film plane.
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